Compare · head to head
Charles River Laboratories vs Medpaces
Medpaces ranks higher overall — 360 rank 96 vs 17.
Charles River Laboratories leads on Value (60 vs 54) and Sentiment (50 vs 43). Medpaces leads on Quality (83 vs 47), Growth (64 vs 36) and Safety (63 vs 19).
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | USA | USA |
| Sector | Health Care | Health Care |
| Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| Size | X-Large | Large |
| ISIN | US1598641074 | US58506Q1094 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | ||
| Ranks | ||
| 360 | 17 | 96 |
| Value | 60 | 54 |
| Quality | 47 | 83 |
| Growth | 36 | 64 |
| Safety | 19 | 63 |
| Sentiment | 50 | 43 |
| Quality details | ||
| Profitability | 44 | 95 |
| Cash Truth | 50 | 71 |
Charles River Laboratories vs InotivCharles River Laboratories vs MaxCyteCharles River Laboratories vs Relay TherapeuticsCharles River Laboratories vs CertaraAdd a third stock →
Full analyses: Charles River Laboratories · Medpaces
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100